Cancer-specific contexts, dictated by oncogenic drivers (e.g., MYC [3, 4], EWS-FLI1 [5, 6]), tumor suppressors (e.g., Parkin [7]), and microenvironmental insults, dynamically tune PHGDH expression and activity. Here, PHGDH is linked to cancer.